1. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection
- Author
-
Luc Bauchet, Luc Taillandier, Philippe Peruzzi, Johan Pallud, Jacques Guyotat, Denys Fontaine, Marie-Hélène Baron, Emmanuel Mandonnet, Valérie Bernier, Laurent Capelle, Hugues Duffau, Réseau d'Etude des Gliomes, REG, Laboratoire d'Imagerie Fonctionnelle (LIF), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-IFR49-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurochirurgie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Neurochirurgie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de neuro-radiologie, CHU Grenoble, Université de Reims Champagne-Ardenne (URCA), Service de neurochirurgie, Hospices Civils de Lyon (HCL), Centre Alexis Vautrin (CAV), Service de radiothérapie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire d'Imagerie Fonctionnelle ( LIF ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR14-IFR49-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], CHU Nice, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Université de Reims Champagne-Ardenne ( URCA ), Hospices Civils de Lyon ( HCL ), Centre Alexis Vautrin ( CAV ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO)
- Subjects
Male ,MESH : Oligodendroglioma ,MESH : Retrospective Studies ,Databases, Factual ,MESH: Antineoplastic Agents, Alkylating ,Neurosurgical Procedures ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,MESH: Linear Models ,MESH: Magnetic Resonance Imaging ,MESH: Glioma ,0302 clinical medicine ,MESH : Child ,MESH : Linear Models ,MESH: Child ,Medicine ,Statistical analysis ,MESH : Female ,10. No inequality ,Child ,MESH: Middle Aged ,MESH : Neoplasm Recurrence, Local ,MESH: Kinetics ,Brain Neoplasms ,General Medicine ,MESH: Follow-Up Studies ,Glioma ,MESH : Adult ,MESH : Neurosurgical Procedures ,Middle Aged ,Magnetic Resonance Imaging ,3. Good health ,Dacarbazine ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Brain Neoplasms ,Disease Progression ,MESH: Disease Progression ,Female ,Neurosurgery ,MESH : Kinetics ,MESH: Neoplasm Recurrence, Local ,Surgical resection ,Adult ,medicine.medical_specialty ,Adolescent ,MESH : Male ,MESH : Antineoplastic Agents, Alkylating ,Oligodendroglioma ,MESH : Young Adult ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH : Databases, Factual ,Astrocytoma ,MESH: Dacarbazine ,03 medical and health sciences ,Young Adult ,MESH : Adolescent ,MESH : Magnetic Resonance Imaging ,Linear regression ,Grade II Glioma ,Temozolomide ,Humans ,MESH : Middle Aged ,MESH : Brain Neoplasms ,MESH : Dacarbazine ,MESH: Oligodendroglioma ,Antineoplastic Agents, Alkylating ,Retrospective Studies ,Mean diameter ,MESH: Adolescent ,MESH: Humans ,business.industry ,WHO Grade II Glioma ,MESH : Humans ,MESH : Follow-Up Studies ,MESH : Astrocytoma ,MESH: Adult ,MESH: Neurosurgical Procedures ,MESH: Retrospective Studies ,MESH : Disease Progression ,MESH: Databases, Factual ,MESH: Male ,Surgery ,Kinetics ,MESH: Astrocytoma ,MESH : Glioma ,Linear Models ,National database ,Neurology (clinical) ,Neoplasm Recurrence, Local ,Nuclear medicine ,business ,MESH: Female ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
International audience; Grade II gliomas grow slowly and linearly (at rates about 4 mm/year) before undergoing anaplastic transformation. In order to analyze how surgery may affect radiological grade II glioma kinetics, we restrospectively reviewed our national database searching for patients operated on for a supratentorial grade II glioma between 1997 and 2007. We selected patients with at least two postoperative MRI with a minimal delay of 6 months. For each patient, postoperative residues were segmented on successive MRIs. Velocities of diameter expansion were estimated by linear regression of mean diameter evolution for each patient. Fifty-four patients fulfilled inclusion criteria. Median postoperative follow-up was 1.6 years with, on average, 3.4 MRI examinations per patient. Postoperative growth rates of mean diameter were normally distributed, around a mean value of 4.3 mm/year (SD = 3.2 mm/year). Statistical analysis showed no difference between this distribution and the distribution of preoperative growth rates in a previous series of 143 grade II gliomas. For a subset of 23 patients, delay between first MRI and surgery made it possible to estimate also preoperative growth rates. Intrapatient comparison revealed that growth rates were grossly unchanged for 80% of cases. In summary, inter- and intrapatient comparison of pre- and postoperative growth rates proves that surgery does not change grade II glioma dynamics, thus, acting as a cytoreduction.
- Published
- 2009
- Full Text
- View/download PDF